PAI
VIVO

Pittenger & Anderson Inc’s Meridian Bioscience Inc VIVO Stock Holding History

Pittenger & Anderson Inc’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,715
Closed -$25K – 422
2017
Q3 		$25K Buy
+1,715
New +$24.5K ﹤0.01% 303

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Pittenger & Anderson Inc's VIVO Position: Q4 2017 in Review

Pittenger & Anderson Inc sold out of Meridian Bioscience Inc (VIVO) in Q4 2017, closing a stake of 1,715 shares — an estimated $25K sold.

Pittenger & Anderson Inc first reported a position in VIVO in Q3 2017 and held it in 1 quarter. The position peaked at $25K in Q3 2017. 178 funds tracked by Wall St. Rank hold VIVO as of Q4 2017.

  • Pittenger & Anderson Inc reported no remaining Meridian Bioscience Inc position as of Q4 2017 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 1,715 Meridian Bioscience Inc shares in Q4 2017, an estimated $25K.
  • Pittenger & Anderson Inc first reported a position in Meridian Bioscience Inc in Q3 2017 and held it in 1 quarter.
  • Pittenger & Anderson Inc's Meridian Bioscience Inc position peaked at $25K in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2017.

Based on Pittenger & Anderson Inc's 13F filing for Q4 2017, filed 13 Feb 2018.